Cantor Fitzgerald Raises Regeneron Price Target on Dupixent Strength

Cantor Fitzgerald has revised its stock price target for Regeneron Pharmaceuticals upward. The strong performance of the drugmaker's product Dupixent was influential in this decision by the analysis firm. The positive outlook on Dupixent's sales momentum and market share supported optimism regarding Regeneron's financial prospects. Cantor Fitzgerald analysts highlighted the critical role of this product in the company's revenue structure and raised the target price. The target price increase stands out as a development that could positively affect investors' perception of Regeneron stock. Dupixent's strong trajectory also supports expectations for the company's long-term growth potential. Dupixent, which holds an important place in Regeneron's portfolio, is considered among the factors strengthening the company's position in the competitive environment of the biotechnology sector. Not investment advice.

📊 REGN — Piyasa Yorumu

▲ up · 55%

The price target upgrade for Regeneron serves as a positive catalyst, with the Dupixent effect cited as supporting the fundamental outlook. However, the price has risen 18.8% in 24 hours and the RSI stands at 87.8, placing it in overbought territory; MACD is positive but above its signal line. Although short-term momentum is upward, the risk of profit-taking is high. Therefore, I see the direction as upward but keep confidence at a moderate level. A volatile but slightly positive trend is expected over the next 1-3 days.

RSI 14

87.8

MACD

34.18

24h Δ

18.78%

Canlı Grafikler